According to Avidity Biosciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.43226. At the end of 2022 the company had a P/E ratio of -6.66.
Year | P/E ratio | Change |
---|---|---|
2022 | -6.66 | 2.6% |
2021 | -6.49 | -44.86% |
2020 | -11.8 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 13.7 | -283.67% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 11.2 | -250.93% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | -14.9 | 100.28% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | -2.85 | -61.60% | ๐บ๐ธ USA |
Fate Therapeutics
FATE | -2.32 | -68.75% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | -0.0676 | -99.09% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | N/A | N/A | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | 13.9 | -287.63% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.